GLP-1 Market
LLY $1184.63 ▼ -0.0% NVO $38.31 ▼ -1.0% PFE $28.72 • 0.0% VKTX $31.81 ▼ -3.7% KLRA $10.99 ▼ -1.2% GPCR $32.69 ▼ -6.8% RHHBY $52.25 ▼ -2.1%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

AZD9550

AZD9550

Company
AstraZeneca
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 30, 2026

Find a Clinical Trial Near Me

See recruiting studies for AZD9550 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07013643

    A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity

    Not yet reported AstraZeneca 50 participants Est. completion 2027-07-09 2 sites Stand-alone
    Other conditions: Healthy Participants
    View official trial listing →
  • Recruiting NCT NCT07546760

    A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234

    Not yet reported AstraZeneca 28 participants Est. completion 2027-02-04 4 sites Stand-alone
    Other conditions: Hepatic Impairment
    View official trial listing →
  • Completed NCT NCT05848440

    A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants

    Not yet reported AstraZeneca 48 participants Est. completion 2023-11-13 1 site Stand-alone
    Other conditions: Non-alcoholic Steatohepatitis
    View official trial listing →
  • Active, not recruiting NCT NCT06151964

    A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight

    Not yet reported, Not yet reported AstraZeneca 166 participants Est. completion 2027-01-29 15 sites Stand-alone
    Other conditions: Overweight and Obesity
    View official trial listing →
  • Completed NCT NCT06862791

    A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

    Not yet reported AstraZeneca 377 participants Est. completion 2026-05-11 53 sites Stand-alone
    Other conditions: Obesity or Overweight
    View official trial listing →
  • Active, not recruiting NCT NCT07017179

    This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight

    Not yet reported AstraZeneca 16 participants Est. completion 2026-10-23 3 sites Stand-alone
    Other conditions: Obesity/Overweight
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.